Recent advances in vesicular stomatitis virus-based oncolytic virotherapy: a 5-year update.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of General Virology

• Publication date

  2017-11-16

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1099/jgv.0.000980PMID 29143726PMCID PMC5845697
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy.

  2017cited by this paper
• Ruxolitinib and Polycation Combination Treatment Overcomes Multiple Mechanisms of Resistance of Pancreatic Cancer Cells to Oncolytic Vesicular Stomatitis Virus

  2017cited by this paper
• Curcumin promotes the oncoltyic capacity of vesicular stomatitis virus for the treatment of prostate cancers.

  2017cited by this paper
• Activation of Nrf2 Signaling Augments Vesicular Stomatitis Virus Oncolysis via Autophagy-Driven Suppression of Antiviral Immunity

  2017cited by this paper
• Oncolytic Virotherapy: A Contest between Apples and Oranges.

  2017cited by this paper
• Enhancing the Oncolytic Activity of CD133-Targeted Measles Virus: Receptor Extension or Chimerism with Vesicular Stomatitis Virus Are Most Effective

  2017cited by this paper
• Chikungunya, Influenza, Nipah, and Semliki Forest Chimeric Viruses with Vesicular Stomatitis Virus: Actions in the Brain

  2017cited by this paper
• NK-Cell Recruitment Is Necessary for Eradication of Peritoneal Carcinomatosis with an IL12-Expressing Maraba Virus Cellular Vaccine

  2017cited by this paper
• Combining Oncolytic Virotherapy with p53 Tumor Suppressor Gene Therapy

  2017cited by this paper
• Oncolytic Maraba Virus MG1 as a Treatment for Sarcoma

  2017cited by this paper
• Oncolytic Recombinant Vesicular Stomatitis Virus (VSV) Is Nonpathogenic and Nontransmissible in Pigs, a Natural Host of VSV

  2017cited by this paper
• Inhibitory Receptors Induced by VSV Viroimmunotherapy Are Not Necessarily Targets for Improving Treatment Efficacy.

  2017cited by this paper
• Oncolytic virus synergizes with Smac mimetic compounds to induce rhabdomyosarcoma cell death in a syngeneic murine model

  2016cited by this paper
• Hepatitis C virus core protein enhances hepatocellular carcinoma cells to be susceptible to oncolytic vesicular stomatitis virus through down-regulation of HDAC4.

  2016cited by this paper
• Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia.

  2016cited by this paper
• Vesicular stomatitis virus is a potent agent for the treatment of malignant ascites.

  2016cited by this paper
• Safety Studies in Tumor and Non-Tumor-Bearing Mice in Support of Clinical Trials Using Oncolytic VSV-IFNβ-NIS

  2016cited by this paper
• Prime-boost using Separate Oncolytic Viruses in Combination with Checkpoint Blockade Improves Anti-tumor Therapy

  2016cited by this paper
• Perfusion Pressure Is a Critical Determinant of the Intratumoral Extravasation of Oncolytic Viruses.

  2016cited by this paper
• Combination of Paclitaxel and MG1 oncolytic virus as a successful strategy for breast cancer treatment

  2016cited by this paper
• A PTENtial cause for the selectivity of oncolytic viruses?

  2016cited by this paper
• Oncolytic vesicular stomatitis virus expressing interferon-γ has enhanced therapeutic activity

  2016cited by this paper
• Robust Oncolytic Virotherapy Induces Tumor Lysis Syndrome and Associated Toxicities in the MPC-11 Plasmacytoma Model.

  2016cited by this paper
• Oncolytic Viruses: Therapeutics With an Identity Crisis

  2016cited by this paper
• Application of interferon modulators to overcome partial resistance of human ovarian cancers to VSV-GP oncolytic viral therapy

  2016cited by this paper
• A mathematical approach to virus therapy of glioblastomas

  2016cited by this paper
• Murine Tumor Models for Oncolytic Rhabdo-Virotherapy.

  2016cited by this paper
• N-Myc expression enhances the oncolytic effects of vesicular stomatitis virus in human neuroblastoma cells

  2016cited by this paper
• Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodies

  2016cited by this paper
• Novel biomarkers of resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus

  2016cited by this paper
• Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy

  2016cited by this paper
• Constrained evolvability of interferon suppression in an RNA virus

  2016cited by this paper
• Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling.

  2016cited by this paper
• Lassa-Vesicular Stomatitis Chimeric Virus Safely Destroys Brain Tumors

  2015cited by this paper
• Induction of apoptosis in pancreatic cancer cells by vesicular stomatitis virus.

  2015cited by this paper
• Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer

  2015cited by this paper
• Retargeting Oncolytic Vesicular Stomatitis Virus to Human T-Cell Lymphotropic Virus Type 1-Associated Adult T-Cell Leukemia

  2015cited by this paper
• An unexpected inhibition of antiviral signaling by virus-encoded tumor suppressor p53 in pancreatic cancer cells.

  2015cited by this paper
• Microtubule disruption synergizes with oncolytic virotherapy by inhibiting interferon translation and potentiating bystander killing

  2015cited by this paper
• Livin modulates the apoptotic effects of vesicular stomatotitis virus in lung adenocarcinoma.

  2015cited by this paper
• Attenuation of vesicular stomatitis virus infection of brain using antiviral drugs and an adeno-associated virus-interferon vector.

  2015cited by this paper
• PET imaging of oncolytic VSV expressing the mutant HSV-1 thymidine kinase transgene in a preclinical HCC rat model.

  2015cited by this paper
• STAT3 inhibition reduces toxicity of oncolytic VSV and provides a potentially synergistic combination therapy for hepatocellular carcinoma

  2015cited by this paper
• Mechanistic insights into the oncolytic activity of vesicular stomatitis virus in cancer immunotherapy

  2015cited by this paper
• The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.

  2015cited by this paper
• Changes in Susceptibility to Oncolytic Vesicular Stomatitis Virus during Progression of Prostate Cancer

  2015cited by this paper
• Oncolytic potency of HER-2 retargeted VSV-FH hybrid viruses: the role of receptor ligand affinity

  2015cited by this paper
• Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis

  2015cited by this paper
• Evidence for differential viral oncolytic efficacy in an in vitro model of epithelial ovarian cancer metastasis

  2015cited by this paper
• Breaking resistance of pancreatic cancer cells to an attenuated vesicular stomatitis virus through a novel activity of IKK inhibitor TPCA-1.

  2015cited by this paper
• Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study

  2015cited by this paper
• Revisiting STAT3 signalling in cancer: new and unexpected biological functions

  2014cited by this paper
• Definitive Management of Oligometastatic Melanoma in a Murine Model Using Combined Ablative Radiation Therapy and Viral Immunotherapy.

  2014cited by this paper
• Maraba virus as a potent oncolytic vaccine vector.

  2014cited by this paper
• Type III Interferon Attenuates a Vesicular Stomatitis Virus-Based Vaccine Vector

  2014cited by this paper
• Oncogenic Ras inhibits IRF1 to promote viral oncolysis

  2014cited by this paper
• Preclinical safety and activity of recombinant VSV‐IFN‐β in an immunocompetent model of squamous cell carcinoma of the head and neck

  2014cited by this paper
• Re-engineering vesicular stomatitis virus to abrogate neurotoxicity, circumvent humoral immunity, and enhance oncolytic potency.

  2014cited by this paper
• Molecular determinants of susceptibility to oncolytic vesicular stomatitis virus in pancreatic adenocarcinoma.

  2014cited by this paper
• MUC1: a multifaceted oncoprotein with a key role in cancer progression.

  2014cited by this paper
• Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer.

  2014cited by this paper
• Experimental Evolution of an Oncolytic Vesicular Stomatitis Virus with Increased Selectivity for p53-Deficient Cells

  2014cited by this paper
• Maraba MG1 virus enhances natural killer cell function via conventional dendritic cells to reduce postoperative metastatic disease.

  2014cited by this paper
• Faster Replication and Higher Expression Levels of Viral Glycoproteins Give the Vesicular Stomatitis Virus/Measles Virus Hybrid VSV-FH a Growth Advantage over Measles Virus

  2014cited by this paper
• Suppression of autophagic genes sensitizes CUG2-overexpressing A549 human lung cancer cells to oncolytic vesicular stomatitis virus-induced apoptosis.

  2014cited by this paper
• Vesiculovirus Neutralization by Natural IgM and Complement

  2014cited by this paper
• Using Targeted Virotherapy to Treat a Resistant Ewing Sarcoma Model: From the Bedside to the Bench and Back

  2014cited by this paper
• Aptamer-facilitated Protection of Oncolytic Virus from Neutralizing Antibodies

  2014cited by this paper
• Reporter gene imaging identifies intratumoral infection voids as a critical barrier to systemic oncolytic virus efficacy

  2014cited by this paper
• Bacterial-mediated knockdown of tumor resistance to an oncolytic virus enhances therapy.

  2014cited by this paper
• The strength of the T cell response against a surrogate tumor antigen induced by oncolytic VSV therapy does not correlate with tumor control.

  2014cited by this paper
• BCL-2 inhibitors sensitize therapy-resistant chronic lymphocytic leukemia cells to VSV oncolysis.

  2013cited by this paper
• Triptolide-mediated inhibition of interferon signaling enhances vesicular stomatitis virus-based oncolysis.

  2013cited by this paper
• Safety Studies on Intravenous Administration of Oncolytic Recombinant Vesicular Stomatitis Virus in Purpose-Bred Beagle Dogs

  2013cited by this paper
• Neuroattenuation of Vesicular Stomatitis Virus through Picornaviral Internal Ribosome Entry Sites

  2013cited by this paper
• Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling.

  2013cited by this paper
• Small cell ovarian carcinoma: genomic stability and responsiveness to therapeutics

  2013cited by this paper
• Model-based rational design of an oncolytic virus with improved therapeutic potential

  2013cited by this paper
• Characteristics of Oncolytic Vesicular Stomatitis Virus Displaying Tumor-Targeting Ligands

  2013cited by this paper
• Meningeal myeloma deposits adversely impact the therapeutic index of an oncolytic VSV

  2013cited by this paper
• Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8+ T-cell responses to anticancer vaccines

  2013cited by this paper
• Myeloid-derived suppressor cells as a vehicle for tumor-specific oncolytic viral therapy.

  2013cited by this paper
• Cancer upregulated gene 2, a novel oncogene, enhances migration and drug resistance of colon cancer cells via STAT1 activation.

  2013cited by this paper
• PEGylation of Vesicular Stomatitis Virus Extends Virus Persistence in Blood Circulation of Passively Immunized Mice

  2013cited by this paper
• Retargeting Vesicular Stomatitis Virus Glycoprotein Pseudotyped Lentiviral Vectors with Enhanced Stability by In Situ Synthesized Polymer Shell

  2013cited by this paper
• Engineering a serum-resistant and thermostable vesicular stomatitis virus G glycoprotein for pseudotyping retroviral and lentiviral vectors

  2013cited by this paper
• The potential of recombinant vesicular stomatitis virus-mediated virotherapy against metastatic colon cancer.

  2013cited by this paper
• Vesicular Stomatitis Virus Variants Selectively Infect and Kill Human Melanomas but Not Normal Melanocytes

  2013cited by this paper
• Oncolytic vesicular stomatitis virus as a treatment for neuroendocrine tumors.

  2013cited by this paper
• Overcoming cancer cell resistance to VSV oncolysis with JAK1/2 inhibitors

  2013cited by this paper
• Variation in susceptibility of human malignant melanomas to oncolytic vesicular stomatitis virus.

  2013cited by this paper
• Understanding and altering cell tropism of vesicular stomatitis virus.

  2013cited by this paper
• Cancer upregulated gene 2, a novel oncogene, confers resistance to oncolytic vesicular stomatitis virus through STAT1-OASL2 signaling

  2013cited by this paper
• Oncolytic Vesicular Stomatitis Virus in an Immunocompetent Model of MUC1-Positive or MUC1-Null Pancreatic Ductal Adenocarcinoma

  2013cited by this paper
• Suppression of antiviral innate immunity by sunitinib enhances oncolytic virotherapy.

  2013cited by this paper
• The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated mice.

  2013cited by this paper
• Non-replicating rhabdovirus-derived particles (NRRPs) eradicate acute leukemia by direct cytolysis and induction of antitumor immunity

  2013cited by this paper
• Amalgamating oncolytic viruses to enhance their safety, consolidate their killing mechanisms, and accelerate their spread.

  2013cited by this paper
• Antifibrotic properties of transarterial oncolytic VSV therapy for hepatocellular carcinoma in rats with thioacetamide-induced liver fibrosis.

  2013cited by this paper
• Ablation of Nectin4 Binding Compromises CD46 Usage by a Hybrid Vesicular Stomatitis Virus/Measles Virus

  2013cited by this paper

• Exploring the inherent susceptibility of cancer-associated fibroblasts to oncolytic virus infection

  2026cites this paper
• Vesicular Stomatitis Virus-Based Oncolytic Virotherapy: Recent Progress and Emerging Trends

  2025cites this paper
• Mammalian innate antiviral defenses: beyond interferon

  2025cites this paper
• Constitutive NF-kB Activation Is Amplified by VSV in Aggressive PC3 Prostate Cancer Cells That Resist Viral Oncolysis

  2025cites this paper
• Revolutionizing cancer treatment with oncolytic viruses: From tumor targeting and metabolic reprogramming to immune activation and precision delivery

  2025cites this paper
• Recombinant Oncolytic Vesicular Stomatitis Virus Expressing Mouse Interleukin-12 and Granulocyte-Macrophage Colony-Stimulating Factor (rVSV-dM51-mIL12-mGMCSF) for Immunotherapy of Lung Carcinoma

  2025influential citation
• Viral warfare: unleashing engineered oncolytic viruses to outsmart cancer’s defenses

  2025cites this paper
• Activation and Evasion of the FEAR Pathway by RNA Viruses

  2025cites this paper
• Mechanism of action of over-expressing NY-ESO-1 in vesicular stomatitis virus and its combination therapy with NY-ESO-1 TCR-T

  2025cites this paper
• The dual promise of oncolytic viruses: selective targeting and therapeutic enhancement in cancer treatment

  2025cites this paper
• Viral‐Directed Augmentation of Kupffer Cell Cross‐Presentation Provokes Antitumor Immunity Against Liver Metastasis

  2025cites this paper
• Advances in Oncolytic Viral Therapy in Melanoma: A Comprehensive Review

  2025cites this paper
• Bacterial effector screening reveals RNF214 as a virus restriction factor in mammals

  2025cites this paper
• A Comprehensive Review of Modern Cancer Therapies Utilizing Oncolytic Viruses

  2025cites this paper
• Fostamatinib (R788), a spleen tyrosine kinase inhibitor, sensitizes pancreatic cancer cells to oncolytic vesicular stomatitis virus

  2025cites this paper
• Characterization of the Anti-Viral and Vaccine-Specific CD8+ T Cell Composition upon Treatment with the Cancer Vaccine VSV-GP

  2024cites this paper
• Recombinant VSVs: A Promising Tool for Virotherapy

  2024cites this paper
• [The impact of innate immune response on the efficacy of oncolytic viruses].

  2024cites this paper
• Vesicular Stomatitis Virus: Insights into Pathogenesis, Immune Evasion, and Technological Innovations in Oncolytic and Vaccine Development

  2024cites this paper
• Oncolytic Vesicular Stomatitis Virus: Optimisation Strategies for Anti-Cancer Therapies.

  2024cites this paper
• Clinical and Translational Landscape of Viral Gene Therapies

  2024cites this paper
• Bacterial Effector Screening Reveals RNF214 as a Virus Restriction Factor in Mammals

  2024cites this paper
• Unlocking the potential: a specific focus on vesicular stomatitis virus as a promising oncolytic and immunomodulatory agent in cancer therapy

  2024influential citation
• Fed‐batch strategies for intensified rVSV vector production in high cell density cultures of suspension HEK293 cells

  2024cites this paper
• Finding Hopf bifurcation islands and identifying thresholds for success or failure in oncolytic viral therapy.

  2024cites this paper
• Gene therapy clinical trials worldwide to 2023—an update

  2024cites this paper
• Mathematical modelling of reoviruses in cancer cell cultures

  2024cites this paper
• Tutorial: design, production and testing of oncolytic viruses for cancer immunotherapy

  2024cites this paper
• A Method for the Production of Recombinant VSVs with Confirmation of Biological Activity

  2024cites this paper
• Immune landscape and response to oncolytic virus-based immunotherapy

  2024cites this paper
• The infectious haemorrhagic syndrome virus (IHSV) from rice-field eel (Monopterus albus): Isolation, genome sequence, cross-infection and induced-immune response in Chinese perch (Siniperca chuatsi)

  2024cites this paper
• Two Point Mutations in the Glycoprotein of SFTSV Enhance the Propagation Recombinant Vesicular Stomatitis Virus Vectors at Assembly Step

  2023cites this paper
• Development of Recombinant Oncolytic rVSV-mIL12-mGMCSF for Cancer Immunotherapy

  2023cites this paper
• Oncolytic Therapy of Solid Tumors by Modified Vesicular Stomatitis Virus

  2023cites this paper
• The potential of swine pseudorabies virus attenuated vaccine for oncolytic therapy against malignant tumors

  2023cites this paper
• A promising future in cancer immunotherapy: Oncolytic viruses.

  2023cites this paper
• Intertumoral heterogeneity impacts oncolytic vesicular stomatitis virus efficacy in mouse pancreatic cancer cells

  2023cites this paper
• Oncolytic Viruses and Immune Checkpoint Inhibitors: The “Hot” New Power Couple

  2023cites this paper
• Oncolytic virotherapy using neural stem cells as a novel treatment option for glioblastoma multiforme

  2023cites this paper
• Vesicular Stomatitis Virus (VSV) G Glycoprotein Can Be Modified to Create a Her2/Neu-Targeted VSV That Eliminates Large Implanted Mammary Tumors

  2023cites this paper
• Construction of VSVΔ51M oncolytic virus expressing human interleukin-12

  2023cites this paper
• Efficacy of coxsackievirus A21 against drug-resistant neoplastic B cells.

  2023cites this paper
• Exploiting RIG-I-like receptor pathway for cancer immunotherapy

  2023cites this paper
• Phase I study of VSV-GP (BI 1831169) as monotherapy or combined with ezabenlimab in advanced and refractory solid tumors.

  2022cites this paper
• Oncolytic viruses in immunotherapy

  2022cites this paper
• Infection of non-cancer cells: A barrier or support for oncolytic virotherapy?

  2022cites this paper
• Virus-like Particles: Measures and Biological Functions

  2022cites this paper
• Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma

  2022cites this paper
• Characterization of Morreton virus as an oncolytic virotherapy platform for liver cancers

  2022cites this paper
• Immunotherapy by mesenchymal stromal cell delivery of oncolytic viruses for treating metastatic tumors

  2022influential citation
• Evaluation of Host Cell Impurity Effects on the Performance of Sterile Filtration Processes for Therapeutic Viruses

  2022cites this paper
• Win or loss? Combination therapy does improve the oncolytic virus therapy to pancreatic cancer

  2022cites this paper
• Oncolytic Viruses: Immunotherapy Drugs for Gastrointestinal Malignant Tumors

  2022cites this paper
• Immunovirotherapy Based on Recombinant Vesicular Stomatitis Virus: Where Are We?

  2022cites this paper
• Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements

  2022cites this paper
• Multi-modal efficacy of a chimeric vesiculovirus expressing the Morreton glycoprotein in sarcoma

  2022cites this paper
• Cellular resistance to an oncolytic virus is driven by chronic activation of innate immunity

  2022cites this paper
• Repeated dosing improves oncolytic rhabdovirus therapy in mice via interactions with intravascular monocytes

  2022cites this paper
• Nonclinical pharmacokinetics and biodistribution of VSV-GP using methods to decouple input drug disposition and viral replication

  2022cites this paper
• Characterization of Morreton Virus (MORV) as a Novel Oncolytic Virotherapy Platform for Liver Cancers

  2022cites this paper
• Generation of SARS-CoV-2 Spike Pseudotyped Virus for Viral Entry and Neutralization Assays: A 1-Week Protocol

  2021cites this paper
• Viral vector‐based gene therapies in the clinic

  2021cites this paper
• LDL receptor and pathogen processes: Functions beyond normal lipids.

  2021cites this paper
• Differential infection of murine and human dendritic cell subsets by oncolytic vesicular stomatitis virus variants

  2021cites this paper
• Antifibrotic Therapy Augments the Antitumor Effects of Vesicular Stomatitis Virus Via Reprogramming Tumor Microenvironment

  2021cites this paper
• Combining Oncolytic Viruses and Small Molecule Therapeutics: Mutual Benefits

  2021cites this paper
• Chandipura virus induces cell death in cancer cell lines of human origin and promotes tumor regression in vivo

  2021cites this paper
• Fighting cancer with oncolytic viral therapy: identifying threshold parameters for success

  2021cites this paper
• Combinatorial Approaches for Cancer Treatment Using Oncolytic Viruses: Projecting the Perspectives through Clinical Trials Outcomes

  2021cites this paper
• Development of Group B Coxsackievirus as an Oncolytic Virus: Opportunities and Challenges

  2021influential citation
• Oncolytic Viruses as Nanomedicines against the Tumor Microenvironment

  2021cites this paper
• Experimental virus evolution in cancer cell monolayers, spheroids, and tissue explants

  2021cites this paper
• Defective Interfering Genomes and the Full-Length Viral Genome Trigger RIG-I After Infection With Vesicular Stomatitis Virus in a Replication Dependent Manner

  2021cites this paper
• Expanding the Spectrum of Pancreatic Cancers Responsive to Vesicular Stomatitis Virus-Based Oncolytic Virotherapy: Challenges and Solutions

  2021cites this paper
• Oncolytic Virotherapy and Microenvironment in Multiple Myeloma

  2021cites this paper
• Chemogenetic ON and OFF switches for RNA virus replication

  2021cites this paper
• Inhibition of glioma using a novel non-neurotoxic vesicular stomatitis virus.

  2021cites this paper
• A mathematical model for the role of macrophages in the persistence and elimination of oncolytic viruses

  2020cites this paper
• Crosstalk between oncolytic viruses and autophagy in cancer therapy.

  2020cites this paper
• The role of cancer metabolism in defining the success of oncolytic viro-immunotherapy.

  2020cites this paper
• Characterization of the Impact of Oncolytic Vesicular Stomatitis Virus on the Trafficking, Phenotype, and Antigen Presentation Potential of Neutrophils and Their Ability to Acquire a Non-Structural Viral Protein

  2020cites this paper
• Oncolytic virotherapy: Challenges and solutions.

  2020cites this paper
• Oncolytic Virus with Attributes of Vesicular Stomatitis Virus and Measles Virus in Hepatobiliary and Pancreatic Cancers

  2020cites this paper
• Collateral Lethal Effects of Complementary Oncolytic Viruses

  2020cites this paper
• A critical role for MSR1 in vesicular stomatitis virus infection of the central nervous system

  2020influential citation
• Engineering multiple levels of specificity in an RNA viral vector

  2020cites this paper
• Oncolytic vesicular stomatitis viruses selectively target M2 macrophages.

  2020cites this paper
• Examination of vesicular stomatitis virus-induced morphology changes in individual Vero cells by QMod microscopy.

  2020cites this paper
• Development of oncolytic virotherapy: from genetic modification to combination therapy

  2020cites this paper
• Virus–Receptor Interactions: Structural Insights For Oncolytic Virus Development

  2019cites this paper
• Experimental Evolution Generates Novel Oncolytic Vesicular Stomatitis Viruses with Improved Replication in Virus-Resistant Pancreatic Cancer Cells

  2019cites this paper
• Flavonoids as P-gp inhibitors: a systematic review of SARs.

  2019cites this paper
• Virus – Receptor Interactions: Structural Insights For Oncolytic Virus Development

  2019cites this paper
• Vesiculopolins, a New Class of Anti-Vesiculoviral Compounds, Inhibit Transcription Initiation of Vesiculoviruses

  2019cites this paper
• Cell Death Mechanisms in Esophageal Squamous Cell Carcinoma Induced by Vesicular Stomatitis Virus Matrix Protein

  2019cites this paper
• Immune Effects of M51R Vesicular Stomatitis Virus Treatment of Carcinomatosis From Colon Cancer.

  2019cites this paper
• Directed evolution as a tool for the selection of oncolytic RNA viruses with desired phenotypes

  2019influential citation
• NF-κB Signaling in Targeting Tumor Cells by Oncolytic Viruses—Therapeutic Perspectives

  2018cites this paper
• Structure-Function Relationships of the Nucleocapsid in Vesicular Stomatitis Virus

  2018cites this paper
• Enhanced Safety and Efficacy of Oncolytic VSV Therapy by Combination with T Cell Receptor Transgenic T Cells as Carriers

  2018cites this paper